Clinical trials: Diabetes Type II
Type 2 Diabetes Mellitus
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"
The purpose of this study is to investigate the safety and efficacy of long-term treatment with pioglitazone (Actos Tablets) in the routine clinical setting in combination with an insulin product in patients with type 2 diabetes…
- Trial name
- NCT02068508
- Testing
- Pioglitazone
- Volunteers
- 1,067 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus.
- Trial name
- NCT00767000
- Testing
- MK-0941, Lantus, Metformin
- Volunteers
- 813 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type II
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
This study is going to assess the safety and tolerability of PF-06291874 in adults with Type 2 Diabetes Mellitus as monotherapy, to evaluate the significance of overall glycemic control in these subjects.
- Trial name
- NCT02175121
- Testing
- PF-06291874
- Where
- 19 sites in United States
- Volunteers
- 172 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
This trial is conducted globally. The aim of this trial is to compare stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2…
- Trial name
- NCT02453685
- Testing
- biphasic insulin aspart 30, insulin glargine, insulin aspart
- Where
- 41 sites in Australia, Bulgaria and 7 more
- Volunteers
- 335 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
Despite the development of novel treatments, cardiovascular disease (CVD) remains the leading cause of death and disability. It has been observed in clinical practice, that the use of novel glycemia-lowering therapies with…
- Trial name
- NCT05256706
- Testing
- SomaSignal Informed Medical Management SSCVD, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 143 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)
This is a multi-center, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with Type 2 diabetes mellitus (DM) who have been treated with sulphonylurea (SU)…
- Trial name
- NEEDS (NCT01285076)
- Testing
- Other: Retrospective chart review; one participant encounter visit.
- Where
- Taiwan
- Volunteers
- 834 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic diseases with a complex, multifactorial etiology, and is a chronic disease with various clinical and biochemical manifestations.
- Trial name
- NCT05479435
- Testing
- Blue Prescription Exercise Program, Video Based Home Exercise Program, Supervised Group Exercise Program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul Medipol University Hospital
Type 2 Diabetes Mellitus
MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)
A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00532935
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 517 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
- Trial name
- SCORE (NCT00960076)
- Testing
- Saxagliptin, Metformin XR
- Where
- 35 sites in United States, Colombia and 3 more
- Volunteers
- 282 people
- Sponsor
- AstraZeneca
Pre-diabetes, Type 2 Diabetes
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
This study evaluates exenatide, sitagliptin, and glimepiride for the treatment of high blood sugar in patients with impaired fasting glucose or early type 2 diabetes.
- Trial name
- NCT00775684
- Testing
- Exenatide, Sitagliptin, Glimepiride
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Pennsylvania
Insulin Resistance
Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals With Insulin Resistance
The overall aim of the project is to determine whether or not exercise influences cardiovascular or nervous responses to meal ingestion in individuals with insulin resistance or type 2 diabetes.
- Trial name
- NCT00954109
- Testing
- Exercise
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- US Department of Veterans Affairs
Type2 Diabetes
Blueberry Consumption and Type 2 Diabetes
Lifestyle strategies that include dietary modification, such as consumption of a plant-based diet, are well recognized in disease prevention and may improve type 2 diabetes.
- Trial name
- NCT02972996
- Testing
- Blueberry
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Albany Research Institute, Inc.
Diabetes Mellitus, Type 2, Newly Diagnosed
Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients
The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2…
- Trial name
- NCT01147627
- Testing
- exenatide injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R, Pioglitazone
- Where
- 25 sites in China
- Volunteers
- 416 people
- Sponsor
- Sun Yat-sen University
Diabetes Mellitus, Type 2
Diabetes Disparities: Texting to Extend Treatment (DD-TXT)
One way to help Veterans improve their diabetes control is through the use of technology to help provide information, motivation, and reminders necessary to support diabetes self-management.
- Trial name
- DD-TXT (NCT04227379)
- Testing
- Intervention 1- DSMS+, Comparison - DSMS
- Where
- 3 sites in United States
- Volunteers
- 366 people
- Sponsor
- VA Office of Research and Development
Diabetes, Type 2 Diabetes Mellitus
Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
This trial is conducted in Asia. The aim of the trial is to compare efficacy and safety of thrice daily versus twice daily NovoMix® 30 (Biphasic insulin aspart 30) in subjects with type 2 diabetes inadequately controlled with…
- Trial name
- NCT02582242
- Testing
- biphasic insulin aspart 30
- Where
- 50 sites in Algeria, China and 5 more
- Volunteers
- 437 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (NAFLD) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir…
- Trial name
- NCT00998335
- Testing
- Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 2
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and…
- Trial name
- NCT01106690
- Testing
- Canagliflozin, Sitagliptin, Metformin
- Where
- 83 sites in United States, Canada and 9 more
- Volunteers
- 344 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.
- Trial name
- NCT02288273
- Testing
- Bydureon
- Where
- 29 sites in United States
- Volunteers
- 239 people
- Sponsor
- AstraZeneca
Diabetes
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its…
- Trial name
- NCT01107717
- Testing
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.